key: cord-0709193-vge9fx8g
authors: van Loon, Welmoed; Rössig, Heike; Burock, Susen; Hofmann, Jörg; Bernhard, Julian; Linzbach, Elisabeth; Pettenkofer, Domenika; Schönfeld, Christian; Gertler, Maximilian; Seybold, Joachim; Kurth, Tobias; Mockenhaupt, Frank P.
title: Emergence of SARS-CoV-2 B.1.1.7 Lineage at Outpatient Testing Site, Berlin, Germany, January–March 2021
date: 2021-07-03
journal: Emerg Infect Dis
DOI: 10.3201/eid2707.210845
sha: be61ff041588c776a667a661ccd8e5d450b45227
doc_id: 709193
cord_uid: vge9fx8g

Within 5 weeks in 2021, B.1.1.7 became the dominant severe acute respiratory syndrome coronavirus 2 lineage at an outpatient testing site in Berlin, Germany. Compared with outpatients with wild-type virus infection, patients with B.1.1.7 had similar cycle threshold values, more frequent sore throat and travel history, and less frequent anosmia/ageusia.

and half (49%) reported contact with a SARS-CoV-2positive person (Table) .

Most assessed characteristics did not substantially differ between patients with wild-type or B.1.1.7, including age, sex, leading symptoms, symptom duration, contact with a SARS-CoV-2-positive person, and time passed since contact (Table) . However, B.1.1.7 patients had traveled more frequently than those with the wild-type strain (19% vs. 10%). Patients with B.1.1.7 more often reported sore throat than did patients with wild-type virus (54% vs. 42%) but less frequently reported anosmia or ageusia (24% vs. 38%) (Table) . We observed no difference in cycle threshold (C t ) values for the envelope gene target between B.1.1.7 and wild-type samples (median 20.2 vs. 20.1) (Table) . In patients reporting a symptom duration of >7 days, C t values appeared to be lower for those with B.1.1.7 (26.2 vs. 30.1 for wild-type), but the difference was not significant (p = 0.7 by Mann-Whitney U test) (Table; Figure 2 ).

Finally, we explored which combination of variables in our dataset best described B.1.1.7 in a logistic regression applying a backward stepwise selection on the basis of the Akaike information criterion (Appendix). This work identified the best set of associated factors as the absence of anosmia or ageusia (p = 0.01), longer symptom duration (p = 0.02), sore throat (p = 0.05), lower C t value (p = 0.07), travel in the previous 14 days (p = 0.08), lower age (p = 0.09), and absence of rhinorrhea (p = 0.12). We then used the bootstrap technique to repeat the variable selection in 1,000 replicated datasets and evaluated how often these variables were selected with the backward selection. This analysis resulted in anosmia or ageusia, 89%; symptom duration, 78%; travel, 73%; sore throat, 68%; C t value, 66%; age, 56%; and rhinorrhea, 51%. Absence of anosmia or ageusia, longer symptom duration, and travel were selected most often, indicating their association with B.1.1.7 infection. We performed all analyses in R version 3.6.3 (https://cran.r-project.org).

The first B.1.1.7 case in Germany was recorded in late December 2020 (5) . At our testing site, B.1.1.7 was observed 3 weeks later and replaced wild-type virus as the dominant strain within just 5 weeks. The rapid emergence and dominance of this lineage likely results from its increased transmissibility (E. Volz et al., unpub. data), which is potentially caused by spike protein polymorphisms (including 501Y) conferring enhanced mucosal binding (6) Compared to the wild-type virus, B.1.1.7 is reportedly associated with more deaths in nonhospitalized patients but not in inpatients (1, 2) . In our young outpatient study population, we did not observe major, lineage-dependent differences in leading symptoms. Nevertheless, anosmia and ageusia, among the most specific coronavirus disease symptoms (3), were less common in patients with B.1.1.7., whereas sore throat was more common. A survey in the United Kingdom revealed patients with B.1.1.7 experienced anosmia and ageusia less frequently but more frequently experienced sore throat, cough, fatigue, myalgia, and fever (8) . In contrast, no associations between SARS-CoV-2 B.1.1.7 and self-reported symptoms, disease duration, or hospital admissions were seen in another UK study (9) . The main factors for B.1.1.7 infection prediction in our study appeared to be lack of anosmia or ageusia and longer symptom duration, in addition to recent travel. The association with recent travel at the time of B.1.1.7 spread is probably no longer relevant because B.1.1.7 is now the most common variant in Berlin and Germany.

With regard to C t values, one study observed simi- C t values (indicating higher viral load) have been observed compared to wild-type samples. Lower C t values were also seen in other studies on population (11) and inpatient levels (2). In our cross-sectional assessment of recently ill outpatients, we did not observe such differences. Still, increased transmissibility may result from the variant's prolonged excretion (10; S.M. Kissler et al., unpub. data). Test timing appears crucial for interpretation of C t values. Outpatients are commonly tested earlier than inpatients. The combination of prolonged viral shedding with different test timing might explain increased viral load in B.1.1.7 samples in inpatients but not in recently ill outpatients. In outpatients with ≥7 days symptom duration, C t values in B.1.1.7 samples were suggestively reduced. However, comparison groups were small. Our data enabled detection of a maximum effect size on overall C t values, which corresponds to B.1.1.7 C t values being 1.5 units below or 1.0 above those for wild-type virus.

The main limitation of our study was its limited subgroup sizes, which reduced the likelihood of detecting differences between rare characteristics. Other limitations are the 1-time assessment, subjective symptom duration, and the variable manifestation of SARS-CoV-2 infection (3). Strengths include standardized procedures conducted by trained medical staff and its prospective nature evaluating patient groups during the same period, reducing the likelihood of biases because of temporal effects.

In summary, SARS-CoV-2 VOC B.1.1.7 is now the dominant lineage in Berlin. In outpatients, no major difference in clinical manifestations has been observed. This article was preprinted at https://www.medrxiv.org/ content/10.1101/2021.04.15.21255389v1.

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study

Epidemiological and clinical characteristics of SARS-CoV-2 infections at a testing site in

Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic

COVID-19) daily situation report of the Robert Koch Institute

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants

Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation

Coronavirus (COVID-19) infection survey: characteristics of people testing positive for COVID-19 in England

COVID-19 Genomics UK (COG-UK) Consortium. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs

S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR

We thank the Corona Untersuchungsstelle staff at the Charité-Universitätsmedizin Berlin for their dedication and hard work during the coronavirus disease pandemic.

Ms. Van Loon is a PhD student at the Research Group Malaria and Infectious Diseases Epidemiology, Institute of Tropical Medicine and International Health, Charité-Universitätsmedizin Berlin, Germany. Her primary research interests include the epidemiology of infectious diseases.